Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

@article{Qiang2015TreatmentWT,
  title={Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus},
  author={Shirong Qiang and Yusuke Nakatsu and Yasuyuki Seno and Midori Fujishiro and Hideyuki Sakoda and Akifumi Kushiyama and Keiichi Mori and Yasuka Matsunaga and Takeshi Yamamotoya and Hideaki Kamata and Tomoichiro Asano},
  journal={Diabetology & Metabolic Syndrome},
  year={2015},
  volume={7},
  pages={1-7}
}
BackgroundInsulin resistance with elevated glucose is a risk factor for non-alcoholic steatohepatitis (NASH). We investigated the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor luseogliflozin on NASH development using a rodent model.MethodsMice were treated with both nicotinamide and streptozotocin (NA/STZ) to reduce insulin secretory capacity, and then fed a high fat diet containing trans fatty acids (HFDT) for 8 weeks. The NA/STZ HFDT-fed mice were divided into two groups… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 32 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

Similar Papers